Bristol Myers Squibb (BMY) Change in Acquisitions & Divestments (2009 - 2026)

Bristol Myers Squibb has disclosed Change in Acquisitions & Divestments across 18 years of filings, most recently posting $391.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 77.73% year-over-year to $391.0 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 260.67% YoY), while the FY2025 annual figure was $2.0 billion, up 76.02% from the prior year.
• Change in Acquisitions & Divestments slipped to $391.0 million in Q1 2026, from $402.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for BMY reached as high as $5.1 billion in Q3 2022 and fell as low as -$762.0 million in Q3 2024.
• The 5-year median for Change in Acquisitions & Divestments is $391.0 million (2026), against an average of $625.4 million.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments surged 2750.0% — and 2024, when it slumped 221.92%.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $1.2 billion in 2022, then tumbled by 96.6% to $41.0 million in 2023, then jumped by 2490.24% to $1.1 billion in 2024, then slumped by 62.15% to $402.0 million in 2025, then dropped by 2.74% to $391.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $391.0 million, $402.0 million, and $829.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.